Log In
BCIQ
Print this Print this
 

AK106-001616 (formerly AK106)

  Manage Alerts
Collapse Summary General Information
Company Asahi Kasei Pharma Corp.
DescriptionCytosolic phospholipases A2 (PLA2) inhibitor
Molecular Target Phospholipase A2 (PLA2)
Mechanism of ActionPhospholipase A2 inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today